ZA200608239B - Therapeutic combination for treatment of Alzheimers disease - Google Patents

Therapeutic combination for treatment of Alzheimers disease Download PDF

Info

Publication number: ZA200608239B
Authority: ZA; South Africa
Prior art keywords: active; pharmaceutically acceptable; alzheimer; disease; acetylcholine esterase
Prior art date: 2004-04-14

Application number

ZA200608239A

Other languages

English (en)

Inventor

Gregg H Larson

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-14

Filing date

2006-10-03

Publication date

2008-06-25

2006-10-03 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2008-06-25 Publication of ZA200608239B publication Critical patent/ZA200608239B/en

Links

208000024827 Alzheimer disease Diseases 0.000 title claims description 69
230000001225 therapeutic effect Effects 0.000 title description 7
150000003839 salts Chemical class 0.000 claims description 75
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 62
239000008194 pharmaceutical composition Substances 0.000 claims description 52
241000124008 Mammalia Species 0.000 claims description 49
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 38
239000003085 diluting agent Substances 0.000 claims description 38
239000003937 drug carrier Substances 0.000 claims description 36
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 28
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 28
229960005370 atorvastatin Drugs 0.000 claims description 28
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 26
230000000694 effects Effects 0.000 claims description 13
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims description 12
229960001770 atorvastatin calcium Drugs 0.000 claims description 12
229960003530 donepezil Drugs 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 7
230000006641 stabilisation Effects 0.000 claims description 7
238000011105 stabilization Methods 0.000 claims description 7
230000000051 modifying effect Effects 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 5
230000000087 stabilizing effect Effects 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 4
230000008859 change Effects 0.000 claims description 3
208000024891 symptom Diseases 0.000 claims description 3
XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 claims 1
108090001069 Chymopapain Proteins 0.000 claims 1
239000004480 active ingredient Substances 0.000 description 64
150000001875 compounds Chemical class 0.000 description 40
238000000034 method Methods 0.000 description 28
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
201000010099 disease Diseases 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
239000002552 dosage form Substances 0.000 description 15
235000012000 cholesterol Nutrition 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 8
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 8
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 8
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 8
206010012289 Dementia Diseases 0.000 description 7
230000032683 aging Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
238000012545 processing Methods 0.000 description 5
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
230000009467 reduction Effects 0.000 description 4
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
229960001685 tacrine Drugs 0.000 description 3
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
239000006053 animal diet Substances 0.000 description 2
229940039856 aricept Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229940108366 exelon Drugs 0.000 description 2
229960004844 lovastatin Drugs 0.000 description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
230000002981 neuropathic effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
208000037259 Amyloid Plaque Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
206010054880 Vascular insufficiency Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000003941 amyloidogenesis Effects 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
229940127226 anticholesterol agent Drugs 0.000 description 1
FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
229960005110 cerivastatin Drugs 0.000 description 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000006999 cognitive decline Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
230000006870 function Effects 0.000 description 1
229960003980 galantamine Drugs 0.000 description 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
230000036433 growing body Effects 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940002661 lipitor Drugs 0.000 description 1
208000027061 mild cognitive impairment Diseases 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007137 neurofibrillary pathology Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229960002965 pravastatin Drugs 0.000 description 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229960004136 rivastigmine Drugs 0.000 description 1
229960000672 rosuvastatin Drugs 0.000 description 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000023577 vascular insufficiency disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

ZA200608239A 2004-04-14 2006-10-03 Therapeutic combination for treatment of Alzheimers disease ZA200608239B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US56214104P	2004-04-14	2004-04-14

Publications (1)

Publication Number	Publication Date
ZA200608239B true ZA200608239B (en)	2008-06-25

Family

ID=34963723

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200608239A ZA200608239B (en)	2004-04-14	2006-10-03	Therapeutic combination for treatment of Alzheimers disease

Country Status (14)

Country	Link
EP (1)	EP1737539A1 (ko)
JP (1)	JP2007532624A (ko)
KR (1)	KR20060133008A (ko)
CN (1)	CN1960781A (ko)
AU (1)	AU2005232447A1 (ko)
BR (1)	BRPI0509881A (ko)
CA (1)	CA2562069A1 (ko)
IL (1)	IL178120A0 (ko)
MX (1)	MXPA06011969A (ko)
NO (1)	NO20065196L (ko)
RU (1)	RU2006136361A (ko)
TW (1)	TW200533341A (ko)
WO (1)	WO2005099823A1 (ko)
ZA (1)	ZA200608239B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI432195B (zh)	2007-10-03	2014-04-01	Kowa Co	神經細胞死亡抑制劑
PL3413870T3 (pl) *	2016-02-11	2022-01-10	Sigmathera Sas	Igmezyna do zastosowania do leczenia choroby alzheimera
CA3142164A1 (en) *	2019-06-14	2020-12-17	Joshua O. Atiba	Triple pharmaceutical composition for proteinaceous infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020028826A1 (en) *	2000-06-15	2002-03-07	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
NZ536111A (en) *	2002-04-02	2006-03-31	Janssen Pharmaceutica Nv	Statin therapy for enhancing cognitive maintenance
AU2003298514A1 (en) *	2002-05-17	2004-05-04	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
MXPA05006940A (es) *	2002-12-24	2006-02-22	Neurochem Int Ltd	Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2004071431A2 (en) *	2003-02-05	2004-08-26	Myriad Genetics, Inc.	Method and composition for treating neurodegenerative disorders
WO2004082706A2 (en) *	2003-03-19	2004-09-30	Ares Trading S.A.	Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
US20050090449A1 (en) *	2003-05-13	2005-04-28	Boehringer Ingelheim International Gmbh	Novel statine derivatives for the treatment of Alzheimer's disease

2005
- 2005-04-04 AU AU2005232447A patent/AU2005232447A1/en not_active Abandoned
- 2005-04-04 RU RU2006136361/15A patent/RU2006136361A/ru not_active Application Discontinuation
- 2005-04-04 MX MXPA06011969A patent/MXPA06011969A/es unknown
- 2005-04-04 JP JP2007507862A patent/JP2007532624A/ja not_active Withdrawn
- 2005-04-04 BR BRPI0509881-5A patent/BRPI0509881A/pt not_active IP Right Cessation
- 2005-04-04 EP EP05718393A patent/EP1737539A1/en not_active Withdrawn
- 2005-04-04 KR KR1020067021174A patent/KR20060133008A/ko not_active Application Discontinuation
- 2005-04-04 CN CNA2005800173902A patent/CN1960781A/zh active Pending
- 2005-04-04 WO PCT/IB2005/000923 patent/WO2005099823A1/en active Application Filing
- 2005-04-04 CA CA002562069A patent/CA2562069A1/en not_active Abandoned
- 2005-04-13 TW TW094111657A patent/TW200533341A/zh unknown
2006
- 2006-09-14 IL IL178120A patent/IL178120A0/en unknown
- 2006-10-03 ZA ZA200608239A patent/ZA200608239B/en unknown
- 2006-11-13 NO NO20065196A patent/NO20065196L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BRPI0509881A (pt)	2007-10-16
TW200533341A (en)	2005-10-16
JP2007532624A (ja)	2007-11-15
IL178120A0 (en)	2006-12-31
RU2006136361A (ru)	2008-04-20
NO20065196L (no)	2007-01-03
MXPA06011969A (es)	2006-12-15
KR20060133008A (ko)	2006-12-22
CA2562069A1 (en)	2005-10-27
CN1960781A (zh)	2007-05-09
WO2005099823A1 (en)	2005-10-27
EP1737539A1 (en)	2007-01-03
AU2005232447A1 (en)	2005-10-27

Publication	Publication Date	Title
Kerola et al.	2011	The complex interplay of cardiovascular system and cognition: how to predict dementia in the elderly?
Nair et al.	1995	Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo
EP0671171A1 (en)	1995-09-13	Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events
KR20060040676A (ko)	2006-05-10	알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
EP2291191A1 (en)	2011-03-09	Methods for preventing and treating neurodegenerative diseases
AU2023208107A1 (en)	2023-08-17	Composition comprising an anti-Αβ protofibril antibody and a beta- secretase BACE1 inhibitor for the treatment of Alzheimer's disease
ZA200608239B (en)	2008-06-25	Therapeutic combination for treatment of Alzheimers disease
KR20010033003A (ko)	2001-04-25	스타틴-카르복시알킬에테르 병용 제제
RU2388479C1 (ru)	2010-05-10	Способ коррекции гиперхолестеринемии
JP2005526806A (ja)	2005-09-08	認知障害の治療法
CA2382548C (en)	2007-07-03	Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
Tonstad et al.	2004	Management of hyperlipidemia in the pediatric population
Kurata et al.	2001	Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
JP2007513991A (ja)	2007-05-31	メタボリック症候群の処置のためのスタチンの使用
RU2058144C1 (ru)	1996-04-20	Средство для лечения сердечной недостаточности
JP2024507810A (ja)	2024-02-21	高脂血症又は混合型脂質異常症に罹患しているスタチン不耐性患者における使用のためのオビセトラピブ及びエゼチミブの併用療法
Goldberg et al.	2004	1084-174 Efficacy of ezetimibe-10 mg/day coadministered with multiple doses of simvastatin in patients with primary hypercholesterolemia
CA3227153A1 (en)	2023-02-02	Treatment of his hyporesponders
AU2013202455B2 (en)	2015-05-07	Methods for preventing and treating neurodegenerative diseases
JPH04112823A (ja)	1992-04-14	痴呆治療剤
Dastani	2005	Assessment of drug utilization patterns, medication compliance and physician adherence to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid system
Goldberg	1997	The impact of lipid lowering in coronary artery disease
JPH0449235A (ja)	1992-02-18	痴呆治療剤
UA59412C2 (uk)	2003-09-15	Спосіб лікування хвороби альцгеймера (варіанти), фармацевтична композиція фанхінону (варіанти) та набір